GSE158765
Platelet mRNA in response to antiplatelet therapy exposure
The purpose of this study was to identify changes in platelet mRNA that result from exposure to antiplatelet therapy.  A total of 84 healthy volunteers were recruited into a longitudinal study of various antiplatelet exposures with 58 completing all study visits.  This was a 5 visit study where each visit was separated by ~ 4 weeks.  At each Visit purified platelets using a CD45 negative selection protocol was performed in addition to platelet function testing using light transmittance aggregometry (ADP, EPI, and Collagen) and PFA100 (Col/EPI).  After the baseline visit (V1), participants were randomized to receive 81mg/day or 325mg/day aspirin x 4 weeks followed by Visit 2.  Participants then crossed over to the alternative dose of aspirin for 4 weeks followed by Visit 3.  Between Visits 3 and 4 participants washed out their aspirin for 4 weeks.  The final exposure was ticagrelor 90mg twice daily x 4 weeks until Visit 5. Overall design: Randomized cross over clinical trial of daily 81 mg apsirin, 325 mg aspirin, aspirin washout, and 180 mg Ticagerlor.